Beyang Therapeutics

Shenzhen Beyang Therapeutics Co., Ltd. is an innovative biopharmaceutical company that utilizes its proprietary ExCEED platform to accelerate the discovery and development of new drugs targeting unmet clinical needs. Beyang has established the proprietary computer-accelerated drug discovery integration platform ExCEED, which leverages novel molecular generation and optimization methods, MMPT, along with computational DMPK simulation predictions, to guide the discovery and development of preclinical candidate molecules. This significantly shortens the optimization time from hit compounds to clinical candidates, improving the efficiency of drug R&D. The company focuses on disease areas with unmet clinical needs, such as ophthalmology and oncology, aiming to become the "DreamWorks" of the global new drug R&D industry. It fully leverages the team's expertise in the early stages of drug discovery, advancing both self-developed pipelines and collaborative or licensed-out development (License-out or Co-development) strategies.